Home›Trial›NCT07652736
NCT07652736Recruiting

A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

Study Summary

The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice

Conditions
Advanced Non-Small Cell Lung CancerExtensive-Stage Small Cell Lung Cancer
Interventions / Drugs
Tislelizumab
View on ClinicalTrials.gov ↗
Sponsor
BGNE
BeiGene Ltd
Oncology
C63/100
Study Details
Enrollment440 participants
Primary Completion—
Lead SponsorBeOne Medicines
Data Retrieved2026-08-02 04:04:45.566850+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 440 participants
Sponsor Catalyst Profile

BeiGene Ltd (BGNE) is the sponsoring company for this trial. BiotechSign currently grades this company C (63/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BGNE Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence